Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies

被引:1
|
作者
Sugiura-Ogasawara, Mayumi [1 ]
Atsumi, Tatsuya [2 ]
Yamada, Hideto [3 ]
Kitaori, Tamao [1 ]
Ozaki, Yasuhiko [1 ]
Katano, Kinue [1 ]
Murashima, Atsuko [4 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Nagoya, Aichi 4678601, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan
[3] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 657, Japan
[4] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan
关键词
Antiphospholipid antibody; lupus anticoagulant; obstetric antiphospholipid syndrome; recurrent pregnancy loss; survey; RECURRENT PREGNANCY LOSS; ASPIRIN PLUS HEPARIN; LUPUS ANTICOAGULANT; ANTICARDIOLIPIN ANTIBODIES; WOMEN; AUTOANTIBODIES; PREDICTOR; RECOGNIZE; UPDATE; TRIAL;
D O I
10.3109/14397595.2015.1023978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The international classification criteria (CC) for definite antiphospholipid syndrome (APS) recommend confirmation of the sustained presence, for at least 12 weeks, of both lupus anticoagulant (LA), as determined by aPTT and RVVT, and anti beta 2glycoprotein I (beta 2GPI) or anticardiolipin (aCL) IgG and/or IgM. However, it remains unclear whether obstetricians comply with the aforementioned CC for the diagnosis of APS in daily clinical practice. We performed a nationwide survey to examine the attitudes of Japanese obstetricians toward the use of assays for antiphospholipid antibodies (aPLs). Methods. A questionnaire was sent to 2,700 obstetric facilities where maternity checkups are car-ried out. The types of assays conducted for aPLs, ascertainment of persistence of the antibodies for at least 12 weeks, and the cutoff points used for the assays were examined. Results. Of the facilities surveyed, 61.5% carried out the assay(s) only once. In regard to the type of assay performed, 97.1% carried out the assay for aCL IgG and/or beta 2GPI-dependent aCL, while 67.9% performed the LA-aPTT and/or LA-RVVT assay. Only 8.8% carried out assays for both LA. As for the cutoff points used, 98% of the facilities used lower cutoff points described in the manufacturers' manuals rather than the cutoff values recommended in the CC. Conclusion. Thus, only a limited number of facilities adhered precisely to the CC for the diagnosis of APS. Inappropriate treatment and unnecessary expense are potentially major concerns when facilities overdiagnose APS using lower cutoff points or without ascertaining the persistence of the antibodies for at least 12 weeks. On the other hand, some patients miss the opportunity to be treated for APS because of the absence of testing for LA.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [41] Real-World Thrombectomy Using the Sofia Catheter
    Nouri, Nasreddine
    Ferrigno, Marc
    Personnic, Thomas
    Bala, Fouzi
    Bretzner, Martin
    Estrade, Laurent
    Pruvo, Jean-Pierre
    Henon, Hilde
    Kazemi, Apolline
    Bricout, Nicolas
    WORLD NEUROSURGERY, 2019, 122 : E1247 - E1251
  • [42] Real-world evidence in the treatment of ovarian cancer
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2017, 28 : 61 - 65
  • [43] The effectiveness of fingolimod in a Portuguese real-world population
    Correia, I.
    Batista, S.
    Marques, I. B.
    Sousa, M.
    Ferreira, R.
    Nunes, C.
    Macario, M. C.
    Sousa, L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 6 : 41 - 48
  • [44] Real-world treatment chronic migraine in Poland
    Domitrz, Izabela
    Karaszewski, Bartosz
    Stepien, Adam
    ARCHIVES OF MEDICAL SCIENCE, 2024, 20 (06) : 2082 - 2084
  • [45] Real-world appraisal of intracranial pressure monitoring
    Feng, Junfeng
    Yang, Chun
    Jiang, Jiyao
    LANCET NEUROLOGY, 2020, 20 (07) : 502 - 503
  • [46] The use of real-world data in drug repurposing
    Park, Kyungsoo
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2021, 29 (03) : 117 - 124
  • [47] Diversifying Eligibility to Enhance Real-World Results
    Fayyaz, Fatima
    Carvajal, Richard D.
    Devoe, Craig E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3895 - +
  • [48] Management of Dermatophytosis: Real-World Indian Perspective
    Shenoy, Manjunath
    Poojari, Shital
    Rengasamy, Madhu
    Vedmurthy, Maya
    Barua, Shyamanta
    Dhoot, Dhiraj
    Barkate, Hanmant
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2023, 14 (03) : 347 - 356
  • [49] Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: a longitudinal study
    Khabbazi, Alireza
    Gadakchi, Leyla
    Moslemi, Mohammadreza
    Khalaji, Amirreza
    Esalatmanesh, Kamal
    Ziarati Yazdeli, Asma
    Hajialilo, Mehrzad
    Malek Mahdavi, Aida
    CLINICAL RHEUMATOLOGY, 2023, 42 (06) : 1537 - 1544
  • [50] Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
    Nishimura, Tadashi
    Fujimoto, Hajime
    Okano, Tomohito
    Naito, Masahiro
    Tsuji, Chikashi
    Iwanaka, Soichi
    Sakakura, Yasumasa
    Yasuma, Taro
    D'Alessandro-Gabazza, Corina N.
    Oomoto, Yasuhiro
    Gabazza, Esteban C.
    Kobayashi, Tetsu
    Ibata, Hidenori
    CANCERS, 2022, 14 (12)